Abstract: Objective  To observe the clinical efficacy and adverse reactions of raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment. Methods  A total of 42 patients with advanced colorectal cancer were treated with raltitrexed containing regimen. The objective response rate (ORR), disease control rate (DCR), median progressionfree survival (mPFS) and adverse reactions were evaluated. Results  The ORR of the 42 patients was 16.67%, DCR was 80.96%, and mPFS was 4.90 months (95%CI: 2.996.81 months). The most of adverse reactions were gradeⅠ-Ⅱ, including leucopenia (30.95%), thrombocytopenia (2.38%), anemia (40.48%), nausea and vomiting (2.38%), anorexia (4.76%), diarrhea (2.38%), transaminase elevation (47.62%) and fatigue (11.90%). Grade Ⅲ-Ⅳ transaminase elevation was found in only 4.76% of patients. Conclusion  Raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment is effective and well tolerated, and further clinical application is recommended.

Key words: Colorectal neoplasms, Drug therapy, Raltitrexed